All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

IGF-1 LR3 peptide

IGF-1 LR3 peptide is a synthetic analogue of insulin-like growth factor-1 (IGF-1) designed to increase biological stability and extend the duration of activity in experimental settings.

IGF‑1 LR3 is a modified form of Insulin‑like growth factor 1, a hormone involved in regulating cell growth, tissue repair, and metabolic signaling.

Because of its extended half-life, IGF-1 LR3 has been studied in research related to muscle physiology, metabolism, and cellular growth mechanisms.

How IGF-1 LR3 peptide works

IGF-1 LR3 interacts with the IGF-1 receptor, which plays a key role in signaling pathways involved in cellular growth and metabolism. Activation of these pathways may:

  • stimulate cellular growth and protein synthesis

  • influence muscle tissue repair and regeneration

  • regulate metabolic processes related to glucose and nutrient utilization

The LR3 modification alters the peptide structure to:

  • increase resistance to binding proteins

  • extend its circulating half-life

  • prolong biological activity in experimental models

Clinical trials and evidence

Research on IGF-1 and related analogues has been conducted in laboratory studies and clinical investigations exploring metabolic and endocrine signaling. Experimental studies have examined:

  • mechanisms of cell growth and tissue repair

  • IGF-1 signaling in muscle physiology

  • metabolic pathways involved in energy regulation

However, IGF-1 LR3 peptide itself has not undergone extensive clinical trials, and most available data come from experimental research rather than controlled clinical studies.

Possible side effects of IGF-1 LR3 peptide:

Because IGF-1 LR3 influences growth factor signaling, potential side effects may include:

  • headache

  • fatigue

  • hypoglycemia

  • fluid retention

  • injection site reactions

Further research is required to clarify the long-term safety and risks associated with this compound.

IGF-1 LR3 is considered an experimental peptide studied primarily in endocrine and metabolic research and is not approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

IGF-1 LR3
Action: Muscle growth stimulation | Category: growth factor
Experimental dosage: 20–50 mcg | Frequency: daily | Timing: post‑workout | Cycle on: 4–6 weeks — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: 4 weeks
Effectiveness: ■■■▢▢ | Safety: ■■▢▢▢

Related peptides

Peptides from the same functional group:Follistatin 315, Follistatin 344, MGF non PEG, PEG-MGF

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged